

## Q1 2019 Payment Limit Report for Neurology

CMS has released the Q1 2019 drug pricing files for both average sales price (ASP) and not otherwise classified (NOC) drugs. These changes are effective **January 1, 2019**, and will remain in effect until either a correction or the next scheduled update is made by CMS.

The data used for the Q1 2019 reimbursement files is based on the Q3 2018 sales data submitted to CMS by drug manufacturers. We encourage you to review the revised drug payment limit files, including reimbursement allowables on NOC drugs, on the [CMS Website](#).

### 2% Sequestration Cut to Medicare Reimbursements

Due to sequestration, a 2% cut to Medicare payments has been applied to providers with services dates on or after April 1, 2013. As a result, the effective rate for office-administered drugs will be ASP+4.3%. However, the underlying allowable will remain at ASP+6%, which may be a basis for private payer reimbursement rates. We encourage you to check with your private payers to understand their allowable rates for physician fee schedule Part B drugs.

Drug	HCPCS Code	Billing Unit	Q4 2018 ASP+6%	Q1 2019 ASP+6%	% Change
AbobotulinumtoxinA (DYSPORT®)	J0586	5 Unit	\$8.42	\$8.53	1.31%
Alemtuzumab (LEMTRADA®)	J0202	1 MG	\$1,842.13	\$1,882.06	2.17%
Baclofen	J0475	10 MG	\$176.02	\$169.75	-3.57%
Belimumab (BENLYSTA®)	J0490	10 MG	\$44.16	\$44.16	0.01%
Bevacizumab (AVASTIN®)	J9035	10 MG	\$79.25	\$81.18	2.44%
Denosumab injection (XGEVA®, PROLIA®)	J0897	1 MG	\$18.58	\$18.61	0.17%
Immune globulin (BIVIGAM™)	J1556	500 MG	\$70.52	\$70.52	0.00%
Immune globulin (FLEBOGAMMA™)	J1572	500 MG	\$35.07	\$34.40	-1.92%
Immune globulin (GAMMAPLEX®)	J1557	500 MG	\$52.06	\$45.89	-11.86%
Immune globulin (GAMUNEX®-C, GAMMAKED™)	J1561	500 MG	\$39.49	\$40.11	1.58%
Immune globulin (OCTAGAM®)	J1568	500 MG	\$36.72	\$35.47	-3.41%
Immune globulin (PRIVIGEN®)	J1459	500 MG	\$39.63	\$40.32	1.73%
Immune globulin, liquid (GAMMAGARD®)	J1569	500 MG	\$43.14	\$42.23	-2.12%
Immune globulin, powder (CARIMUNE® NF, GAMMAGARD®)	J1566	500 MG	\$37.95	\$43.11	13.62%
Incobotulinumtoxin A (XEOMIN®)	J0588	1 UNIT	\$5.08	\$5.08	-0.08%
Infliximab (REMICADE®)	J1745	10 MG	\$78.83	\$76.65	-2.78%
Natalizumab (TYSABRI®)	J2323	1 MG	\$19.83	\$19.73	-0.49%

<b>Drug</b>	<b>HCPCS Code</b>	<b>Billing Unit</b>	<b>Q4 2018 ASP+6%</b>	<b>Q1 2019 ASP+6%</b>	<b>% Change</b>
Ocrelizumab (OCREVUS)	J2350	1 MG	\$57.34	\$57.37	0.05%
Omalizumab (XOLAIR®)	J2357	5 MG	\$37.07	\$37.05	-0.05%
OnabotulinumtoxinA (BOTOX®)	J0585	1 UNIT	\$6.14	\$6.14	-0.02%
RimabotulinumtoxinB (MYOBLOC®)	J0587	100 UNITS	\$12.03	\$12.00	-0.25%

Confidentiality Notice: This e-mail message is for the sole use of the intended recipients and may contain confidential and privileged information. Any unauthorized review, use, disclosure or distribution is prohibited.

McKesson, 10101 Woodloch Forest Drive The Woodlands, TX 77380  
[msh@mckesson.com](mailto:msh@mckesson.com) [www.mckesson.com/specialty](http://www.mckesson.com/specialty)